Robinhood is falling in love with Dow Jones stock Pfizer after yesterday's vaccine news. That could be a mistake.
Robinhood traders are falling in love with Pfizer stock (NYSE: PFE). They started piling into the Dow Jones Industrial Average component on Wednesday after positive news about a vaccine.
Pfizer jumped 5% on Wednesday after the company announced that the U.S. government had placed an initial order for 100 million doses of the virus vaccine it is developing with BioNTech (NASDAQ: BNTX).
The government agreed to pay $1.95 billion for the vaccine if it proves to be safe and effective.
Pfizer’s gains drove the Dow Jones higher, powering it narrowly past the 27,000 level before the closing bell.
Retail trading has surged in recent months as the stock market recovered from the pandemic crash in March.
And now they’re hoping a vaccine is a path to easy riches.
Robinhood traders are perhaps a little too enthusiastic regarding Pfizer. There’s still a long way to go before its vaccine becomes available. We don’t know yet if the drug will be effective.
Typically, it takes roughly a decade for a new vaccine to go through the various stages of development and testing. However, the urgency of the pandemic … has resulted in a mobilization of global medical resources rarely seen before in human history. Billions of dollars, provided by both the public and the private sectors, are funding the global campaign to develop tests, vaccines, and cures for the virus.
But the next phase will be critical to demonstrate that the potential vaccines can protect against infections.
Pfizer’s rally seems to be based on enthusiasm and hope about the recovery. The same is true of the broader Dow Jones. If there’s any obstacle regarding the development of the vaccine, that could send the stock – and the index – lower.
Hope and enthusiasm do not typically produce sound investment decisions, and retail buyers are notorious for piling into stocks with dubious fundamentals.
With a price-to-earnings (P/E) ratio of 13, Pfizer stock doesn’t immediately look that expensive. It’s ridiculously overvalued relative to its future earnings growth, though. Its price/earnings-to-growth (PEG) ratio is a disappointing 2.6.
The pharmaceutical company’s revenue and earnings are estimated to fall in 2020 by 5.3% and 2.7%, respectively.
While analysts expect growth to return in 2021, it seems prudent to avoid pricing in that growth this far in advance. Especially since so much of PFE’s present valuation is based on drug trials that could still fail.
After all, we’ve seen this movie before.
Gilead Sciences (NASDAQ: GILD) was all the rage in April and May. It’s down 11% from its mid-year high.
The same thing could happen to Pfizer next.
Disclaimer: This article represents the author’s opinion and should not be considered investment or trading advice from CCN.com. The author owns shares of Microsoft (MSFT).
Last modified: September 23, 2020 2:08 PM